[Acute respiratory failure due to Gemcitabine-induced pulmonary toxicity].
Gemcitabine is a therapeutic agent that has been recently employed in the treatment of various cancers. Pulmonary toxicity has rarely been described. We report a case of a patient treated with Gemcitabine who developed acute respiratory symptoms related to a hypersensitivity pneumonia. Despite a severe clinical and radiological presentation, the outcome was favorable with corticosteroid treatment. In the event of respiratory symptoms in patients receiving Gemcitabine further investigations (chest X-ray, thorax CT-scan, bronchoalveolar lavage) are indicated. In view of the severity of pulmonary toxicity that can be caused by Gemcitabine, re-introduction of treatment is not recommended. We compare our case with other published cases of Gemcitabine-induced pulmonary toxicity.
Stern
J B
JB
Département Thoracique, Institut Mutualiste Montsouris, Paris, France. jean-baptiste.stern@imm.fr
Caliandro
R
R
Lamer
C
C
Lenoir
S
S
Théodore
C
C
Grunenwald
D
D
Girard
P
P
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D012130:Respiratory Hypersensitivity / Q000139:chemically induced*; D012131:Respiratory Insufficiency / Q000139:chemically induced*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine